Eli Lilly and Co. (LLY) and Incyte Corp. ( INCY) have been left disappointed, following FDA's refusal to approve Baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis.
from RTT - Biotech http://ift.tt/2oCoHUY
via IFTTT
No comments:
Post a Comment